• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Systematic comparison between BNT162b2 and CoronaVac in the seroprotection against SARS-CoV-2 Alpha, Beta, Gamma, and Delta variants.

作者信息

Au Wing Ying, Ye Chengjin, Briner Sydney Leigh, Suarez Gianmarco Domenico, Han Jeewon, Xu Xinzhou, Park Jun-Gyu, Brindley Melinda Ann, Martinez-Sobrido Luis, Cheung Peter Pak-Hang

机构信息

Department of Chemical Pathology, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, China; Li Ka Shing Institute of Health Sciences, Li Ka Shing Medical Sciences Building, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, China.

Texas Biomedical Research Institute, San Antonio, Texas, U.S.A.

出版信息

J Infect. 2022 May;84(5):e55-e57. doi: 10.1016/j.jinf.2022.02.030. Epub 2022 Mar 2.

DOI:10.1016/j.jinf.2022.02.030
PMID:35245585
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8889726/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1edf/8889726/64b4319f79f4/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1edf/8889726/64b4319f79f4/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1edf/8889726/64b4319f79f4/gr1_lrg.jpg

相似文献

1
Systematic comparison between BNT162b2 and CoronaVac in the seroprotection against SARS-CoV-2 Alpha, Beta, Gamma, and Delta variants.BNT162b2与科兴新冠疫苗针对SARS-CoV-2 Alpha、Beta、Gamma和Delta变体的血清保护作用的系统比较。
J Infect. 2022 May;84(5):e55-e57. doi: 10.1016/j.jinf.2022.02.030. Epub 2022 Mar 2.
2
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.智利科兴和国药疫苗接种后动态 IgG 血清阳性率：哨点监测研究。
Lancet Infect Dis. 2022 Jan;22(1):56-63. doi: 10.1016/S1473-3099(21)00479-5. Epub 2021 Sep 9.
3
Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals.科兴新冠疫苗（CoronaVac）和BNT162b2疫苗在未感染和既往感染个体中诱导产生严重急性呼吸综合征冠状病毒2（SARS-CoV-2）中和抗体的情况。
EBioMedicine. 2022 Apr;78:103972. doi: 10.1016/j.ebiom.2022.103972. Epub 2022 Mar 30.
4
Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.接种科兴新冠疫苗、腺病毒载体新冠疫苗和辉瑞疫苗加强针后对 SARS-CoV-2 变异株的免疫原性和反应原性：一项在泰国健康成年人中开展的开放标签随机研究。
Hum Vaccin Immunother. 2022 Nov 30;18(6):2091865. doi: 10.1080/21645515.2022.2091865. Epub 2022 Jul 11.
5
Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: A randomized trial.单剂量BNT162b2、ChAdOx1 nCoV-19或科兴新冠疫苗对既往感染的成年人针对新冠病毒德尔塔和奥密克戎变异株的免疫原性：一项随机试验。
J Infect. 2022 Oct;85(4):436-480. doi: 10.1016/j.jinf.2022.06.014. Epub 2022 Jun 18.
6
Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.BNT162b2 疫苗和科兴新冠疫苗的免疫原性和反应原性相关性。
mSphere. 2022 Apr 27;7(2):e0091521. doi: 10.1128/msphere.00915-21. Epub 2022 Mar 14.
7
Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine.CoronaVac 加强针接种后对 SARS-CoV-2 抗体反应的动力学。
Emerg Infect Dis. 2022 Jun;28(6):1237-1240. doi: 10.3201/eid2806.220061. Epub 2022 Apr 14.
8
The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants following CoronaVac or ChAdOx1 nCoV-19 primary series.在科兴或牛津阿斯利康新冠疫苗初免系列接种后，四种针对新冠病毒变异株的新冠疫苗加强针的免疫原性和反应原性。
Asian Pac J Allergy Immunol. 2024 Sep;42(3):276-289. doi: 10.12932/AP-160123-1533.
9
Antibody Response to SARS-CoV-2 Vaccines in People with Severe Obesity.严重肥胖人群对 SARS-CoV-2 疫苗的抗体反应。
Obes Surg. 2022 Sep;32(9):2987-2993. doi: 10.1007/s11695-022-06181-y. Epub 2022 Jul 8.
10
Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.BNT162b2 和 CoronaVac 新冠疫苗对奥密克戎 BA.2 亚谱系引起的 SARS-CoV-2 无症状和有症状感染的有效性：一项前瞻性队列研究。
Lancet Infect Dis. 2023 Apr;23(4):421-434. doi: 10.1016/S1473-3099(22)00732-0. Epub 2022 Dec 12.

引用本文的文献

1
Comparison of SARS-CoV-2 IgG responses in hemodialysis patients and healthcare workers after COVID-19 vaccination.新冠病毒疫苗接种后血液透析患者与医护人员中新冠病毒IgG反应的比较。
Front Immunol. 2025 Jul 15;16:1586468. doi: 10.3389/fimmu.2025.1586468. eCollection 2025.
2
Effectiveness of Booster Vaccinations on the Control of COVID-19 during the Spread of Omicron Variant in Malaysia.奥密克戎变异株在马来西亚流行期间，加强针接种对控制 COVID-19 的效果。
Int J Environ Res Public Health. 2023 Jan 16;20(2):1647. doi: 10.3390/ijerph20021647.
3
Antibody efficacy of inactivated vaccine boosters (CoronaVac) against Omicron variant from a 15-month follow-up study.

本文引用的文献

1
Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine.两剂灭活疫苗后科兴疫苗或ZF2001加强针的体液免疫原性和反应原性
Cell Res. 2022 Jan;32(1):107-109. doi: 10.1038/s41422-021-00596-5. Epub 2021 Dec 3.
2
Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.由 SARS-CoV-2 灭活疫苗诱导的抗体和 T 细胞对关注变体的识别。
Front Immunol. 2021 Nov 9;12:747830. doi: 10.3389/fimmu.2021.747830. eCollection 2021.
3
Limited and Short-Lasting Virus Neutralizing Titers Induced by Inactivated SARS-CoV-2 Vaccine.
一项为期15个月的随访研究中灭活疫苗加强针（科兴新冠疫苗）对奥密克戎变异株的抗体效力
J Infect. 2022 Oct;85(4):e119-e121. doi: 10.1016/j.jinf.2022.06.018. Epub 2022 Jun 26.
灭活 SARS-CoV-2 疫苗诱导的有限且短暂的病毒中和滴度。
Emerg Infect Dis. 2021 Dec;27(12):3178-3180. doi: 10.3201/eid2712.211772. Epub 2021 Sep 24.
4
Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.CoronaVac 疫苗诱导的抗体对 alpha、gamma 和 D614G SARS-CoV-2 变异株的中和作用。
J Med Virol. 2022 Jan;94(1):399-403. doi: 10.1002/jmv.27310. Epub 2021 Sep 8.
5
CoronaVac induces lower neutralising activity against variants of concern than natural infection.与自然感染相比，科兴新冠疫苗对变异株的中和活性较低。
Lancet Infect Dis. 2021 Oct;21(10):1352-1354. doi: 10.1016/S1473-3099(21)00568-5. Epub 2021 Aug 26.
6
Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study.巴西在与伽马变异株相关的新冠疫情中，科兴疫苗对老年人的有效性：一项基于病例对照研究的核酸阴性结果研究。
BMJ. 2021 Aug 20;374:n2015. doi: 10.1136/bmj.n2015.
7
Reduced mortality rate after coronavac vaccine among healthcare workers.医护人员接种科兴疫苗后死亡率降低。
J Infect. 2021 Aug;83(2):e20-e21. doi: 10.1016/j.jinf.2021.06.005. Epub 2021 Jun 9.
8
SARS-CoV-2 spike E484K mutation reduces antibody neutralisation.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白E484K突变降低抗体中和作用。
Lancet Microbe. 2021 Jul;2(7):e283-e284. doi: 10.1016/S2666-5247(21)00068-9. Epub 2021 Apr 7.
9
Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization.循环中的新冠病毒变异株的中和敏感性。
N Engl J Med. 2021 Jun 17;384(24):2354-2356. doi: 10.1056/NEJMc2103022. Epub 2021 Apr 6.
10
Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.用于筛选针对 SARS-CoV-2 的中和抗体和抗病毒药物的快速体外检测方法。
J Virol Methods. 2021 Jan;287:113995. doi: 10.1016/j.jviromet.2020.113995. Epub 2020 Oct 14.